Safety, Tolerability, and Pharmacokinetics of Topical Calcitriol Formulation for Treatment of Chemotherapy-Induced Alopecia in Patients Receiving Taxane-Based Regimen: Final Results
May 2019
in “
Journal of clinical oncology
”
Studysummary This Phase 1 study reported that topical application of BPM31543 was safe and well-tolerated in patients receiving taxane-based chemotherapy, with some experiencing less than 50% hair loss, suggesting potential efficacy in reducing chemotherapy-induced alopecia, although no maximum tolerated dose was identified.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on ascopubs.org →